Tech Transfer & CMC Rescue

Design → GMP, without detours

Dual hubs: San Diego, CA (Southern California) & Montréal, Canada
Scope: End-to-end transfers between sites or sponsors; stabilization of at-risk programs; remediation of process, method, or documentation gaps; comparability strategy and execution; requalification/PPQ readiness; continuity planning and rapid re-start for biologics & mAbs, microbial & fungal proteins/enzymes, AAV & pDNA, LNPs (mRNA/siRNA/DNA), and select small molecules.

When programs stall, the cost isn’t just calendar—it’s confidence. MycoVista was built to take ownership fast: we triage, we stabilize, and we re-lock the process with audit-ready artifacts. We map your QTPP → CQAs → CPPs on day one, trace every deviation to the unit operation that caused it, and then re-establish a design space your team can run at 3 a.m. without drama. As a dual-hub CDMO with a unified digital QMS (ALCOA+), we move your work without detours—and with a data trail that convinces.

Why teams choose MycoVista for Tech Transfer & Rescue

Decisive. Technical. Audit-ready. That’s our operating system.

  • Stabilize first, optimize second. We stop the bleeding (yields, OOS/OOT, bioburden, filter collapse), then we raise performance. Not the other way around.
  • Single narrative across modalities. Mammalian, microbial, vector, LNP, and small molecule teams operate from one control-strategy template—your CMC reads like one story.
  • Dual hubs, one truth. San Diego and Montréal run mirrored SOPs, methods, and batch records; method transfer and equivalence metrics are baked in.
  • Evidence over optimism. We tie every fix to a plot, an acceptance criterion, and a signed report. If it won’t scale or pass inspection, it doesn’t ship.

What we mean by “Tech Transfer & CMC Rescue” (scope)

  • Site moves & program onboarding (sponsor → MycoVista; CDMO A → MycoVista; MycoVista hub ↔ hub).
  • Process stabilization for upstream (batch/fed-batch/perfusion; microbial HD; Pichia induction), downstream (capture/polish/viral safety/UF-DF), and formulation/fill–finish (liquid or lyo).
  • Method transfer & harmonization (development → GMP; site-to-site; platform ↔ custom) with phase-appropriate qualification/validation.
  • Comparability protocols for scale, site, raw-material, or process changes, including acceptance windows and bridging analytics.
  • Regulatory remediation (IND/IMPD/BLA sections, reviewer Q&A, data integrity narratives, stability justifications).
  • Continuity & capacity lifts (parallel campaigns, mirrored release, raw-material alternates, and risk-based stocking).
  • Special situations: refolds that won’t close, AAV empty/full instability, pDNA topology loss, LNP Enc% drift or dsRNA rise, Protein A lifetime collapse, endotoxin spikes, detergent residues, filter pressure hockey-sticks, or “hero” cycles that can’t run nights & weekends.

Background: why transfers fail—and how we keep yours from failing

Transfers go sideways for familiar reasons. First, the control strategy wasn’t written down (or wasn’t real). Second, analytics drifted from development intent—different columns, different cells, different answers. Third, scale physics showed up: oxygen, shear, fouling, heat removal, headspace oxygen, or solvent removal that never matched the bench. We fix all three by rebuilding the spine: a defensible QTPP, explicit CQAs, and CPPs tied to data. Then, and only then, we optimize.

Our three-phase framework: Stabilize → Optimize → Re-lock

You will see these words in your Gantt, not just on this page.

  1. Stabilize (days to weeks).
    • Document triage: batch records, deviations/CAPA, EM/utility trends, release/stability data, change controls, and raw-material histories.
    • First-principles checks: oxygen transfer (kLa), mass flux, resin loading, filter capacity curves, temperature ramps, shear windows, Enc%/size windows for LNPs, empty/full tuning for AAV, and pDNA SC topology safeguards.
    • Containment & hygiene: bioburden/endotoxin controls, closed processing options, isolator/RABS feasibility, operator error traps.
    • Hold the line: interim setpoints and alarms so lots stop failing while we learn.
  2. Optimize (weeks to a few months).
    • Targeted DoE: one-factor heroics are how you got here; we map interactions that actually govern your CQAs.
    • Material robustness: resin cycles, filter lots, lipid lots, nuclease lots, feed lots; alternates qualified where justified.
    • Economics with integrity: throughput, cycle time, resin lifetime, solvent and water cuts—only where validation stays clean.
  3. Re-lock (before PPQ or next phase).
    • Design space + control limits written into batch records.
    • Comparability (pre-specified windows; orthogonal confirmation for the attributes that matter most).
    • Lifecycle files updated: validation/qualification, cleaning, E/L (when relevant), stability, and change controls.

The first 10 business days (what actually happens)

You will know exactly where your program stands—fast.

Day 0–2 — Intake & CDA; structured document request; risk register stub (top 10).
Day 3–5 — Stabilization workshop: USP/DSP/analytics/DP in one room; define interim setpoints; agree “do-not-touch” zones; decide what runs now vs what waits.
Day 6–8 — Gap map: methods to transfer/qualify/validate; unit ops with missing ranges; raw-material vulnerabilities; data-integrity and chain-of-custody issues.
Day 9–10 — Action plan: near-term fixes, DoE outline, comparability plan, and a draft regulatory posture (what to tell whom and when).

Deliverables: triage memo, risk heatmap, stabilization SOP addenda, and a working Gantt.

QTPP → CQAs → CPPs (the spine we rebuild)

We write the control strategy in plain language, then in protocols, then into batch records.

  • QTPP: dose/route; potency; purity/residuals; viral/bioburden safety; size/PDI/Enc% (LNP) or empty/full (AAV); pDNA topology; assay/identity and form for small molecules; shelf life and shipping.
  • CQAs: exactly what we will measure and accept: identity/potency, glycan/charge/size variants, HCP/DNA, endotoxin/sterility/mycoplasma, vg titer, full:empty, dsRNA, residual solvents/detergents, residual nuclease/Protein A, residual metals, PSD/form (API), pH/osmolality, headspace oxygen, residual moisture (lyo).
  • CPPs: the knobs we can turn—feed/induction, pH/DO/temperature, cell retention/bleed, pressure/flow/residence times, gradient/ionic strength, TMP/cross-flow, FRR/TFR/N:P (LNP), filtration ΔP/T, lyo shelf temps/pressures, dosing speed/nozzle depth/nitrogen overlay.

Outcome: one document that says what matters and who proves it—and a trail of SOPs and reports that survive audit.

Method transfer & harmonization (analytics that agree)

Analytics is where many transfers fail. We prevent drift before it starts.

  • Transfer protocols with predefined equivalence metrics (bias/precision/linearity/specificity)—no moving targets.
  • Qualification/validation scaled to phase and risk; orthogonal methods for high-impact attributes (e.g., aggregates by SEC-MALS, charge by icIEF, topology for pDNA, dsRNA for mRNA, empty/full confirmation).
  • Data integrity by design: audit trails, access control, instrument qualification, and reference standards managed across hubs.
  • Release continuity: we bridge old → new methods with side-by-side lots or statistical comparability so regulators don’t blink.

Process transfer: upstream, downstream, formulation, and DP

We carry your molecule from flask to dose with a single narrative.

  • Upstream (mammalian & microbial): oxygen transfer realism (kLa vs OUR), shear envelopes, antifoam logic, induction/bleed strategy, stable seed trains, and N-1 perfusion/high-seed when cycle time wins.
  • Downstream: capture loading that doesn’t break at scale; polishing by impurity map (IEX/HIC/MM); viral filtration without hockey-stick pressure; UF/DF that protects activity and avoids new aggregates.
  • Vectors & pDNA: adherent/suspension/fixed-bed AAV with empty/full engineered and confirmed; pDNA alkaline lysis with supercoiled protection and endotoxin control; nuclease residuals defined.
  • Nanoparticles: FRR/TFR/N:P tuned to hold size/PDI/Enc%; TFF without regrets; sterile filtration feasibility tested early; dsRNA detection and control strategy.
  • Fill–finish & lyo: filtration recovery/integrity proven on real bulk; line settings, nitrogen overlays, stoppering/capping windows; lyo cycles designed from physics (collapse/eutectic, anneal, primary/secondary drying), with CCIT and inspection that operators can hold.

Comparability & change management (proving sameness when you move)

We make changes on purpose—with a protocol, not a hope.

  • Analytical similarity protocols with prespecified acceptance windows and orthogonal checks for the attributes that matter most.
  • Lot selection & statistics that show equivalence (or managed differences) without cherry-picking.
  • Regulatory text drafted up front; reviewer Q&A backed by raw data and stats plans—not adjectives.

Regulatory remediation (fix the file, then the future)

We clean the past, and we make the next submission painless.

  • IND/IMPD/BLA sections refreshed to reflect the actual process and methods.
  • Narratives for deviations, CAPA closure, data integrity improvements, and lifecycle validation (cleaning, hold time, viral safety).
  • Stability updates with shelf-life rationale that matches presentation and shipping lanes.
  • Inspection readiness packs: trend reports, validation summaries, media fills/process simulations, and CCIT evidence in one place.

Facilities, continuity & scale (what you can rely on)

  • Mirrored hubs (San Diego & Montréal) with ISO 8/7 suites, closed-processing options, BSL-2 where required, validated utilities, and real-time EM trending.
  • Scale: microbial & fungal to 50,000 L stainless (qualified programs); mammalian single-use 50 L & 250 L GMP with multi-thousand-liter perfusion footprints; AAV adherent/suspension/fixed-bed; LNP microfluidics through production-relevant runs; aseptic vial/PFS/cartridge with lyo.
  • Continuity: raw-material alternates qualified; resin/membrane lifecycle tracking; stocking plans sized to campaign risk; mirrored release packages for parallel campaigns.

Digital backbone: QMS, LIMS, ELN, eBMR/eBR (ALCOA+)

  • Unified digital QMS across hubs: deviation/CAPA, change control, training, and investigations with audit trails.
  • LIMS/ELN with barcoded chain-of-custody, instrument interfaces, and versioning that prevents quiet edits.
  • eBMR/eBR so every intervention ties to a datum; reviewers follow the story without hunting.

Program Onboarding (your first 30 days)

Speed is useful only if outputs are inspection-grade. In the first month you receive:

  1. A phase-appropriate control strategy that maps QTPP → CQAs → CPPs for your modality, plus interim stabilization setpoints to stop failures now.
  2. A method-transfer plan with equivalence metrics, qualification/validation scope, and a comparability protocol for any pending changes (site, scale, raw material, or process).
  3. A Gantt & risk map (FMEA) with Stabilize → Optimize → Re-lock gates, plus a draft regulatory posture (what we will file and when), and a continuity plan (alternates, stocking, parallel capacity).

Start: send the latest batch record, release panel, stability summary, and known pain points. We’ll return a triage memo, a stabilization plan, and a documented path to GMP.

Typical rescue timelines (indicative; biology- and physics-gated)

  • 0–2 weeks: triage, stabilization SOPs, interim setpoints, and first successful lot under guardrails.
  • 3–10 weeks: targeted DoE on the two or three steps actually driving failures; method transfer/qualification; preliminary comparability.
  • 10–16+ weeks: design-space confirmation, process re-lock, validation road-map (cleaning/hold time/viral safety), updated stability bins, and submission-ready text.

We don’t promise dates your molecule won’t keep. We show the gates, the pass criteria, and the fastest safe path.

Frequently asked (straight answers)

Can you take over mid-campaign? Yes—if the risk register says we can keep patients safe and data clean. We’ll stabilize, then finish the run or pause with a documented plan.
Do you re-use our sponsor methods? If fit-for-purpose, yes. If not, we document gaps, close them, and bridge by comparability.
How do you prevent “method drift” between hubs? Mirrored SOPs, shared reference standards, scheduled cross-checks, and transfer protocols with predefined equivalence metrics.
Empty/full at scale is unstable—can you fix it? Often yes. We tune the charge-based step for robustness and confirm with an orthogonal readout; then we lock ranges that operators can hold.
Our LNP won’t filter—now what? We either redesign for a filterable size window or move to validated aseptic processing with isolators and strong EM performance.
pDNA SC content drops in TFF—help? We adjust shear/TMP/diavols, tune conditioning, and validate membranes on real intermediates.
Do you handle OOS/OOT? Yes—SOP-driven investigations, root cause, CAPA, documented closeout; we’ll stand in front of it with you at audit.

Deliverables (what you can hold)

  • Stabilization package: triage memo, risk heatmap, interim setpoints/alarms, and updated SOP addenda.
  • Control strategy (QTPP → CQAs → CPPs) and design space with ranges written into batch records.
  • Method transfer/qualification/validation files, plus comparability reports for site/scale/material changes.
  • Validation dossiers: cleaning, hold time, viral safety (as applicable), and resin/membrane lifecycle summaries.
  • Stability plans/data with shelf-life rationale; regulatory text for IND/IMPD/BLA updates and reviewer Q&A.
  • eBMR/eBR & CoAs tied to sensors, alarms, and interventions; a single PDF pack an auditor can follow in minutes.

A few patterns that make us different

  • Headroom over hero runs. We choose ranges operations can hold—nights, weekends, and audits included.
  • Orthogonal by default. One method convinces; two methods persuade; trending makes it law.
  • One truth, two hubs. The same control strategy follows your program across San Diego & Montréal.
  • No brand worship. We use tools that serve the biology and the audit. If not, we don’t.

Summary — why MycoVista for Tech Transfer & CMC Rescue

Because you don’t need more slideware. You need lots that run, methods that agree, documents that survive inspection, and a calendar that bends back in your favor. We stabilize what you have, optimize what matters, and re-lock the process so you can move from Design → Data → Decision—without detours.

MycoVista | San Diego, CA & Montréal, Canada
Start Program Onboarding → Share your latest batch record, release/stability snapshot, and top three pain points. We’ll return a triage memo, a stabilization plan, and a documented path to GMP.

EN / FR support available.